Yimiao Shenzhou Completes Series E Financing Round, Marking a New Chapter in Its 10th Anniversary Journey Toward Commercialization
Imunopharm
Developer of Gene and Cell Therapy Technologies
SunNovo
Drug Research and Development Service Provider
January 8, 2025, Beijing, China,Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (referred to as "Yimiao Shenzhou" or "the Company") announced the official completion of its Series E financing round worth hundreds of millions of RMB.This round of financing was led byBeijing-Tianjin-Hebei Collaborative Development Industry Investment FundLeading investment,Taiping Healthcare Fund, Capital Development Group, Si Ji Qing Investment,SunNovoFollowed by multiple professional institutions.This is the 10th round of strategic financing completed by Beijing Yimiaoshenzhou Medical Techology Co., Ltd. on the occasion of its 10th anniversary, marking a milestone and a new starting point as the company transitions from clinical research to commercialization after a decade of dedication to independently developed gene and cell therapies.
The funds from this round of financing will be used to support the commercialization layout of the company's first self-developed CAR-T new drug, IM19, promoting it to become a benchmark product for late-stage lymphoma CAR-T treatment in China after its approval, providing patients with a new treatment option. At the same time, it will also accelerate the research and development as well as clinical progress of new technologies and products in major disease areas such as hematological tumors, solid tumors, and autoimmune diseases. This will help build a leading technology platform for next-generation gene and cell drug technologies in China, including rapid CAR-T, universal CAR-T, and gene editing, and advance the establishment of an industry-leading large-scale GMP manufacturing base, injecting strong momentum into the company’s development.
CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., Dr. Ting HeExpressed: Deep gratitude to both new and existing shareholders for their recognition and support. This round of financing marks an important milestone in the 10-year development journey of Beijing Yimiao Shenzhou Medical Technology Co., Ltd. We will take this as an opportunity to fully advance the commercialization of our first CAR-T product, IM19, as well as the research and development layout of CAR-T therapeutic products covering major diseases such as hematological tumors, solid tumors, and autoimmune diseases. We will continue to invest in the research and development of next-generation CAR-T processes and technologies, promote technological iteration and upgrading, and ensure that Beijing Yimiao Shenzhou Medical Technology Co., Ltd. maintains a leading position in the global gene and cell drug competition. Our goal is to develop and produce more new and effective drugs with lower costs, better efficacy, and higher safety, benefiting a wide range of patients, promoting industrial development, and serving Healthy China.
Beijing-Tianjin-Hebei Collaborative Development Industry Investment FundComment: As an investment fund focusing on the coordinated development of the Beijing-Tianjin-Hebei region, Beijing Yimiaoshenzhou Medical Techology Co., Ltd.'s technological innovation and industrialization capabilities in the field of gene and cell drugs align perfectly with our strategy to support high-tech, high-growth enterprises. We believe that through this collaboration, we will not only accelerate the rapid development of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. but also contribute significantly to the coordinated development of the cell therapy industry in the Beijing-Tianjin-Hebei region and the rise of China's cell therapy industry.
Taiping Healthcare FundStated: As an existing shareholder, we are delighted to accompany the long-term growth of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. Taiping Healthcare Fund has long been focusing on innovative medical technologies in the field of major diseases and will adhere to the investment philosophy of patient capital to help China's innovative drugs benefit more patients. After the commercial launch of Yimiaoshenzhou’s products, Taiping Healthcare Fund will continue to promote the deep integration of commercial insurance and innovative drugs, contributing Taiping’s strength to meet patients' clinical needs.
Beijing Prime Growth Pre-incubation Equity Investment FundStatement: As an investment fund within the Shoufa Group system, we are very pleased to participate once again in the financing of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., and to witness the company's growth and progress. This round of financing will provide strong support for Yimiaoshenzhou's research and development and commercialization efforts. We look forward to Yimiaoshenzhou forming a close collaboration with the Global Future Pharmaceutical and Health Industry Incubation Base established by Beijing Shoufa Technology Development Group Technology Service Co., Ltd., achieving more breakthroughs in the field of gene and cell therapy, and bringing more innovative treatment options to patients suffering from serious diseases such as cancer.
Si Ji Qing InvestmentIndicates:As a local enterprise, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. has always been one of the key enterprises that we focus on and support. We hope to take this round of financing as an opportunity to further optimize the business environment, effectively meet the needs of enterprises, fully act as the "local steward" for enterprises, help enterprises develop healthily and rapidly, and achieve a win-win situation in social value and economic benefits.
SunNovoWe are delighted to participate in this round of financing for Beijing Yimiaoshenzhou Medical Techology Co., Ltd. The company's leading position and innovative capabilities in the field of gene and cell therapy have shown us tremendous potential. This round of financing will accelerate the company’s research and development progress in major disease areas, and we look forward to witnessing the innovation and development of China's novel drug industry together with Beijing Yimiaoshenzhou.
// About the Beijing-Tianjin-Hebei Industrial Investment Fund //
The Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund was established in February 2021 by the People's Governments of Beijing, Tianjin, and Hebei provinces in collaboration with the China Development Bank to deeply implement the major national strategy of Beijing-Tianjin-Hebei collaborative development and fully leverage the guiding and amplifying role of fiscal funds from the three regions. The initial scale of the fund is 4.15 billion yuan, with a focus on supporting fields related to regional scientific and technological innovation and high-end manufacturing.
// About Taiping Medical Health Fund //
Taiping Medical and Health Fund is a private equity investment fund managed by Taiping Innovation, a subsidiary of China Taiping Insurance Group, with a registered size of 10 billion yuan. Taiping Group's equity investment business has long focused on the medical and health industry. Under the guidance of the Healthy China strategy, Taiping Innovation closely aligns its investments with Taiping Group’s core insurance business to achieve mutual empowerment between fund investments and the insurance main business, supporting the creation of China Taiping's "Insurance + Medical Care and Wellness" ecosystem. In managing this fund, Taiping Innovation adopts an F+D investment strategy, focusing on sectors including biopharmaceuticals and pharmaceutical outsourcing, medical devices and diagnostics, medical services, biotechnology, and medical informatization, extending to health technology and health consumption.
// About Shoufa Group //
Beijing Capital Science and Technology Development Group was established in December 2014. It is an important carrier for Beijing to accelerate the reform of the science and technology system, promote the reform of public institutions, and establish a "corporate" model for the "pre-incubation" of scientific and technological achievements. It is committed to building a "pre-incubation" innovation service platform with global influence, promoting the landing in Beijing of major scientific and technological achievement projects with significant value both domestically and internationally, where the technology is still in the stage of application exploration or preliminary research.
// About Si Ji Qing Investment //
Sijiqing Investment is an investment company under Sijiqing Town, Haidian District, Beijing. Relying on nearly one million square meters of high-quality park carrier resources within the Sijiqing town area, it closely follows the overall deployment of the 2024 Haidian District Economic and Social High-Quality Development Conference regarding Haidian District’s commitment to "adhering to the leadership of scientific and technological innovation, firmly taking up the banner of leading development in artificial intelligence, continuously strengthening the pharmaceuticals and health industry, and striving to cultivate more innovative industrial clusters with technical dominance and global competitiveness." The company focuses on industries such as pharmaceuticals and health, cybersecurity, and aerospace information. By establishing industrial funds, it drives the transformation of scientific and technological achievements in Haidian District and helps Sijiqing Town quickly achieve a high-level industrial cluster.
// About SunNovo //
Beijing Sunshine Nohe Drug Research Co., Ltd., as a leading Contract Research Organization (CRO) in drug development services in China, not only possesses 36,300 square meters of research and development laboratories and over 80% of its staff dedicated to R&D, but also has established advanced technology platforms across multiple fields such as drug discovery, pharmaceutical research, clinical trials, and bioanalysis. The company maintains strong innovation capabilities, with 12 self-initiated R&D projects in innovative drugs covering various therapeutic areas including pain management, nephrology and dialysis, and oncology supportive care. Several of these projects have no equivalent products currently on the market in China, demonstrating robust R&D momentum and the ability to transform research into tangible results. By continuously increasing investment in R&D and technological innovation, the company provides comprehensive one-stop drug development services to pharmaceutical enterprises and research institutions in China, aiming to help domestic pharmaceutical manufacturers accelerate import substitution and achieve independent innovation.
// About Yimiao Shenzhou //
Yimiao Shenzhou, established in 2015 with its headquarters in Beijing, is a leading innovative pharmaceutical company at the commercialization stage. With the mission of "making cancer no longer an incurable disease," it focuses on applying cutting-edge gene and cell drug technologies to treat major diseases (such as cancer and autoimmune diseases). To date, the company has completed 10 rounds of strategic financing and owns a one-stop independent R&D and industrialization platform for gene and cell drugs. It has mastered several core technologies, won the top prize in the finals of China's Disruptive Technology Innovation Competition, obtained clinical trial approvals for seven Class 1 new drugs, and received Beijing’s first Drug Manufacturing License for gene and cell therapy products. Its R&D pipeline covers hematological cancers such as lymphoma, leukemia, and multiple myeloma, as well as solid tumors like liver cancer, colorectal cancer, and melanoma, positioning it as a leader in the field of gene and cell therapies.
The company has undertaken more than 10 national and provincial research projects, including the Special Project of the Ministry of Science and Technology's Key R&D Program, the National Health Commission's Science and Technology Innovation - 2030 Major Project, the "Challenge Leader" technical project for cell therapy by the National Innovation Center, and Beijing's Major Science and Technology Special Projects. It has obtained important qualifications such as a National High-tech Enterprise, a Beijing Specialized, Precise, Unique and Innovative Enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Outstanding Engineer, Haidian District Haiying Talent of Beijing, Xingguomen Leading Talent of Daxing District in Beijing, the Gold Award (First Place) in Tsinghua University President’s Cup Innovation Challenge, MIT's 35 Innovators Under 35, and Fortune Magazine's 40 Under 40 Business Elites.
